Medetomidine: New hidden danger in opioid withdrawal for inmates

Key Points:

• Medetomidine, a powerful tranquilizer increasingly found laced with fentanyl, causes severe withdrawal symptoms that are difficult to treat, especially in rural jails lacking resources and protocols, leading to life-threatening complications like heart attacks and strokes.
• Allegheny County Jail in Pittsburgh has developed advanced treatment protocols for medetomidine withdrawal, including the use of medications like Ativan, phenobarbital, and opioid use disorder treatments, thanks to collaboration between jail medical staff and local researchers.
• Despite some progress in places like Pittsburgh, many jails nationwide remain unprepared to detect or treat medetomidine withdrawal due to limited access to medications, lack of training, and the inability of standard toxicology tests to identify the drug.
• Federal guidance mandates that jails provide medications for opioid use disorder (MOUD), but fewer than half of U.S. jails currently offer these treatments, partly because Medicaid and insurance cannot fund jail healthcare, creating financial and legal challenges for correctional facilities.
• Experts hope the growing crisis of medetomidine withdrawal will prompt jails to improve opioid use disorder treatment, as inadequate care in incarceration settings contributes to preventable deaths and worsens public health outcomes.